Recent Updates
Recently added Catalysts

ALXN1820

Phase 1

Healthy | Small molecule | Other |AstraZeneca PLC|Last Updated: Aug 20, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment66
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04631562Study of ALXN1820 in Healthy Adult ParticipantsPHASE1 COMPLETED 66Jan 13, 2021Sep 1, 2022Aug 20, 20243 Australia, United Kingdom
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Treatment-related Adverse Events (TEAEs) For ALXN1820 SC And ALXN1820 IV
Cohorts 1 to 6: Baseline up to Day 127; Cohorts 8 to 9: Baseline up to Day 155

An adverse event (AE) was defined as any unfavorable and unintended sign (for example, including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or procedure, whether or not considered related to the medicinal product or procedure, which occurred during the course of the clinical study. TEAEs were defined as any AEs that commenced after the start of administration of study intervention. Serious AEs (SAEs) were defined as any untoward medical occurrence that met at least 1 of the following serious criteria: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, other medically important serious event. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Reported AEs' Section.

Secondary Endpoints
Area Under The Concentration-time Curve (AUC) From Time 0 (Dosing) To Time Infinity (AUC0-inf) And AUC During The Dosing Interval (AUCtau) of Serum ALXN1820 For Single Dose Cohorts
Up to 126 days following the first day of dosing
Area Under The Concentration-time Curve During The Dosing Interval (AUCtau) Of Serum ALXN1820 For Multiple Dose Cohorts
Up to 154 days following the first day of dosing
Maximum Observed Serum Concentration (Cmax) Of Serum ALXN1820 For Single Dose Cohorts
Up to 126 days following the first day of dosing
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
ALXN1820EXPERIMENTALParticipants will receive ALXN1820 SC or ALXN1820 IV according to their assigned cohort. ALXN1820 SC will be evaluated in single and multiple ascending doses while ALXN1820 IV will be evaluated in a single dose cohort only.
PlaceboPLACEBO_COMPARATORParticipants will receive Placebo SC or Placebo IV according to their assigned cohort.
Interventions
NameTypeDescription
ALXN1820 SCDRUGALXN1820 SC will be administered as a manual SC push or SC infusion via a syringe pump. Doses will range from 12.5 milligrams (mg) to a maximum of 2250 mg. Multiple dosing duration will range from 3 to 5 weeks.
ALXN1820 IVDRUGALXN1820 IV (450 mg) will be administered as an IV infusion.
Placebo SCDRUGPlacebo SC will be administered as a manual SC push or SC infusion via a syringe pump.
Placebo IVDRUGPlacebo IV will be administered as an IV infusion.
Unlock Study Design Details
Eligibility Criteria
SexALL
Healthy VolunteersYes
Study Sites3

Inclusion Criteria: * Body weight 50 to 100 kilograms (kg); body mass index 17 to 32 kg/meter squared. * Cohort 9 only: Japanese participants (defined as those participants whose parents and grandparents are both Japanese and who have spent less than 5 years outside of Japan). * Satisfactory medica...

Countries:AustraliaUnited Kingdom
Unlock Eligibility Criteria